News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
501,953 Results
Type
Article (22680)
Company Profile (169)
Press Release (479093)
Multimedia
Podcasts (61)
Webinars (13)
Section
Business (144270)
Career Advice (1053)
Deals (27403)
Drug Delivery (64)
Drug Development (46624)
Employer Resources (99)
FDA (11900)
Job Trends (10727)
News (232794)
Policy (18358)
Tag
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (1737)
Accelerated approval (19)
Adcomms (3)
Allergies (99)
Alliances (42068)
ALS (77)
Alzheimer's disease (1051)
Antibody-drug conjugate (ADC) (283)
Approvals (12209)
Artificial intelligence (514)
Autoimmune disease (95)
Automation (38)
Bankruptcy (219)
Best Places to Work (9095)
BIOSECURE Act (8)
Biosimilars (118)
Biotechnology (119)
Bladder cancer (104)
Brain cancer (45)
Breast cancer (437)
Cancer (3634)
Cardiovascular disease (215)
Career advice (933)
Career pathing (24)
CAR-T (234)
CDC (9)
Celiac Disease (1)
Cell therapy (613)
Cervical cancer (29)
Clinical research (39469)
Collaboration (1499)
Company closure (1)
Compensation (430)
Complete response letters (22)
COVID-19 (1603)
CRISPR (90)
C-suite (640)
Cystic fibrosis (78)
Data (4055)
Decentralized trials (2)
Denatured (29)
Depression (68)
Diabetes (286)
Diagnostics (6125)
Digital health (44)
Diversity (9)
Diversity, equity & inclusion (24)
Drug discovery (205)
Drug pricing (62)
Drug shortages (16)
Duchenne muscular dystrophy (107)
Earnings (55774)
Editorial (22)
Employer branding (10)
Employer resources (94)
Events (72544)
Executive appointments (726)
FDA (14253)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (10)
Funding (1195)
Gene editing (180)
Generative AI (44)
Gene therapy (414)
GLP-1 (529)
Government (2253)
Grass and pollen (5)
Guidances (322)
Healthcare (13981)
HIV (42)
Huntington's disease (18)
IgA nephropathy (42)
Immunology and inflammation (109)
Immuno-oncology (38)
Indications (75)
Infectious disease (1778)
Inflammatory bowel disease (111)
Inflation Reduction Act (7)
Influenza (85)
Intellectual property (191)
Interviews (173)
IPO (13082)
IRA (15)
Job creations (1985)
Job search strategy (756)
JPM (33)
Kidney cancer (8)
Labor market (40)
Layoffs (233)
Leadership (21)
Legal (3851)
Liver cancer (67)
Longevity (8)
Lung cancer (486)
Lymphoma (255)
Machine learning (40)
Management (40)
Manufacturing (654)
MASH (59)
Medical device (13528)
Medtech (13579)
Mergers & acquisitions (15267)
Metabolic disorders (617)
Multiple sclerosis (88)
NASH (3)
Neurodegenerative disease (181)
Neuropsychiatric disorders (28)
Neuroscience (1716)
NextGen: Class of 2026 (5071)
Non-profit (2599)
Now hiring (22)
Obesity (262)
Opinion (171)
Ovarian cancer (147)
Pain (151)
Pancreatic cancer (170)
Parkinson's disease (173)
Partnered (29)
Patents (379)
Patient recruitment (347)
Peanut (43)
People (41928)
Pharmaceutical (31)
Pharmacy benefit managers (11)
Phase 1 (14363)
Phase 2 (17247)
Phase 3 (12046)
Pipeline (3777)
Policy (103)
Postmarket research (958)
Preclinical (5851)
Press Release (67)
Prostate cancer (158)
Psychedelics (17)
Radiopharmaceuticals (252)
Rare diseases (480)
Real estate (4317)
Recruiting (43)
Regulatory (15045)
Reports (24)
Research institute (1754)
Resumes & cover letters (165)
Rett syndrome (25)
RNA editing (12)
RSV (48)
Schizophrenia (57)
Series A (206)
Series B (150)
Service/supplier (10)
Sickle cell disease (48)
Special edition (2)
Spinal muscular atrophy (85)
Sponsored (31)
Startups (2942)
State (2)
Stomach cancer (6)
Supply chain (80)
Tariffs (28)
The Weekly (31)
Vaccines (617)
Venture capital (54)
Weight loss (141)
Women's health (59)
Worklife (9)
Date
Today (16)
Last 7 days (415)
Last 30 days (1435)
Last 365 days (21283)
2026 (2032)
2025 (21647)
2024 (26107)
2023 (30335)
2022 (40319)
2021 (43279)
2020 (41518)
2019 (35634)
2018 (26709)
2017 (24681)
2016 (22859)
2015 (26775)
2014 (19824)
2013 (16705)
2012 (18271)
2011 (18465)
2010 (16394)
Location
Africa (489)
Alabama (75)
Alaska (6)
Arizona (205)
Arkansas (11)
Asia (31465)
Australia (5269)
California (7555)
Canada (2402)
China (832)
Colorado (362)
Connecticut (336)
Delaware (282)
Europe (68700)
Florida (1282)
Georgia (272)
Hawaii (2)
Idaho (50)
Illinois (653)
India (54)
Indiana (442)
Iowa (18)
Japan (363)
Kansas (115)
Kentucky (31)
Louisiana (22)
Maine (61)
Maryland (965)
Massachusetts (5303)
Michigan (320)
Minnesota (532)
Mississippi (6)
Missouri (118)
Montana (30)
Nebraska (20)
Nevada (75)
New Hampshire (85)
New Jersey (2273)
New Mexico (25)
New York (2013)
North Carolina (1109)
North Dakota (10)
Northern California (3401)
Ohio (236)
Oklahoma (21)
Oregon (29)
Pennsylvania (1532)
Puerto Rico (20)
Rhode Island (40)
South America (744)
South Carolina (62)
South Dakota (1)
Southern California (3126)
Tennessee (139)
Texas (1217)
United States (28154)
Utah (229)
Vermont (1)
Virginia (156)
Washington D.C. (35)
Washington State (657)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
501,953 Results for "sol gel technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Sol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier Disease
December 17, 2025
·
6 min read
Press Releases
Sol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 21, 2025
·
14 min read
Press Releases
Sol-Gel Announces Health Canada Approval of EPSOLAY®
September 4, 2025
·
8 min read
Press Releases
Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
August 15, 2025
·
14 min read
Press Releases
Sol-Gel Reports First Quarter 2025 Results
May 23, 2025
·
7 min read
Business
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 20, 2024
·
13 min read
Press Releases
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
April 17, 2025
·
12 min read
Drug Development
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”) today announced that it has begun Phase 3 testing of SGT-610 (patidegib gel, 2%) for Gorlin syndrome with the first patient screened.
November 30, 2023
·
7 min read
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Technologies, Ltd. announced that it received a notification letter on May 21 2024, from the Nasdaq Stock Market LLC Listing Qualifications Department, stating that the Company is not in compliance with the requirement to maintain a minimum bid price of $1 per share, as set forth in Rule 5450 of the Nasdaq Listing Rules, since the closing bid price for the Company’s ordinary Shares listed on Nasdaq was below US$1.00 for 33 consecutive business days.
May 28, 2024
·
6 min read
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Technologies, Ltd. announced that Padagis Israel Pharmaceuticals Ltd, Sol-Gel’s collaboration partner, submitted a first-to-file Abbreviated New Drug Application to the U.S. Food and Drug Administration for Roflumilast Cream, 0.3%, a drug product generic to Zoryve® Cream, indicated for the treatment of plaque psoriasis in patients six years of age and older.
April 1, 2024
·
6 min read
1 of 50,196
Next